Trial: 202011142

Phase II Study of cemiplimab, an anti-PD-1 monoclonal antibody, and ISA101b vaccine in patients with recurrent/metastatic HPV16 positive Oropharyngeal Cancer who have experienced disease progression with prior anti-PD-1 therapy

Phase

II

Principal Investigator

Adkins, Douglas

Disease Site

Lip, Oral Cavity and Pharynx

Learn more about this study at: clinicaltrials.gov